• Founded: 2016
  • Location: Natick, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Oncology, viral infections
  • Drug types: ONC, INF
  • Lead product: HC101
  • Product link: https://hebecellcorp.com/pipelines/
  • Funding: $53M A Aug 2021
  • Investors: Jacobio Pharmaceuticals



job board

Short description:

Cell Therapies

Drug notes:

HC102 Clin0 ovarian cancer; HC103 Clin0 blood malignancies; HC111 Clin0 blood malignancy; HC112 Clin0 colorectal cancer, ovarian cancer; 5 programs RD multiple cancers

Long description:

HebeCell Corp is developing cell-based therapeutics to treat incurable diseases. Named after the Greek Goddess of Youth, HebeCell is using their patented scalable natural killer (NK) cell technology to fight disease and restore cellular health. HebeCell’s protoNKTM cells are derived from human pluripotent stem cells and are developed in an identical manner to NK cells developing in the human body without artificial manipulation. NK cells are unique as they can target and kill specific types of cells - HebeCell’s NK cells are specifically programmed to target only cancer cells and are being investigated for multiple cancer indications.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com